BioXpress Therapeutics SA is a premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive immunity. We have made a commitment to be your partner of choice for the full development of your biosimilar biol...
The article reports on the agreement entered by generic drug developer, AET Biotechnology Ltd., with biotechnology company, BioXpress Therapeutics SA, in developing the monoclonal antibody (MAb) biosimilars. It states that AET Biotech will be responsible for providing further investment in the long ...
Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company...
OriginatorBioXpress Therapeutics ClassAntivirals; Monoclonal antibodies Mechanism of ActionViral fusion protein inhibitors Orphan Drug Status Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. ...
Abzena and BioXpress Therapeutics recently announced their partnership to support biosimilar development for third-party customers. The partnership creates an...
A team of Children's Medical Research Institute (CMRI) scientists has identified a new method for producing a therapeutic product that has the potential to improve the treatment of cancer.
"Finding a reservoir of these inflammation-resolving molecules at bioactive levels was a big surprise for us," said co-corresponding author Charles Serhan, PhD, DSc, director of BWH's Center for Experimental Therapeutics and Reperfusion Injury. "We've identified some of these molecular signals in...
AET BioTech and BioXpress Therapeutics have entered into an agreement to codevelop a biosimilar version of Abbott's tumor necrosis factor inhibitor monoclonal antibody (mAb) adalimumab, currently marketed under the trade name Humira. Both companies will be actively involved in the dev...
Findings from the BIO-RESORT (TWENTE III) trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular...
Perelman Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia (CHOP). "There are limited treatment options to stop uncontrolled bleeding in patients who are using the newer anticoagulant medications." Camire and colleagues are from CHOP and the Perelman School of ...